Abstract: The present invention relates to novel crystal forms of tipifarnib. Compared with the prior art, the crystal forms of tipifarnib have advantages in crystallinity, hygroscopicity, morphology, form stability and chemical stability. The present invention also relates to the preparation methods of crystal forms of tipifarnib, pharmaceutical composition thereof and their use in preparation for treating and/or preventing abnormal cell growth diseases.
Type:
Grant
Filed:
December 8, 2016
Date of Patent:
March 23, 2021
Assignee:
Hangzhou SoliPharma Co., Ltd.
Inventors:
Xiaohong Sheng, Xiaoxia Sheng, Yanli Dai
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
March 23, 2021
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
March 9, 2021
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.
Abstract: The invention relates to the field of medicine, in particular to the field of veterinary medicine. The invention relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.
Type:
Grant
Filed:
December 18, 2013
Date of Patent:
February 23, 2021
Assignee:
BOEHRINGER INGELHEIM VETMEDICA GMBH
Inventors:
Michael Aven, Balazs Albrecht, Benjamin Franzmann, Matthias Hausmann, Janine Lamar, Ingo Lang
Abstract: The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
Type:
Grant
Filed:
December 22, 2016
Date of Patent:
February 16, 2021
Assignee:
Research Triangle Institute
Inventors:
Frank Ivy Carroll, Bruce Edward Blough, Philip Abraham
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
January 12, 2021
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (referred to herein as “BHBA-001”), which, inter alia, is a (selective) retinoic acid receptor beta (RAR?) (e.g., RAR?2) agonist. The present invention also pertains to pharmaceutical compositions comprising such crystalline forms, and the use of such crystalline forms and compositions, both in vitro and in vivo, to (selectively) activate RAR? (e.g., RAR?2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR?(e.g., RAR?2), that are ameliorated by the activation of RAR? (e.g., RAR?2), etc., including, e.g., neurological injuries such as spinal cord injuries.
Type:
Grant
Filed:
June 16, 2017
Date of Patent:
December 22, 2020
Assignee:
King's College London
Inventors:
Ronnie Maxwell Lawrence, Edwin Aret, Alan David Borthwick, Jane Theresa Brown, Jonathan Patrick Thomas Corcoran, Maria Beatriz de Castro Vasconcelos Goncalves, Sarkis Barrett Kalindjian
Abstract: The present invention provides methods for identifying compounds that act as miR-34a modulators. The present invention also provides miR-34a modulators and compositions containing the modulators. The present invention further provides methods for treating diseases by administration of miR-34a modulators.
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
April 25, 2016
Date of Patent:
November 24, 2020
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
Abstract: Provided herein is a novel mitochondrial Angiotensin II type 1 and type 2 AT1R and AT2R receptor which plays a role in protection of mitochondria against oxidative damage. Evidence from animal studies indicates a role for this receptor in preservation of mitochondria and up-regulation of survival genes, anti-inflammatory action, and improvement of wound healing in the skin and soft tissues. Pharmaceutical compositions for treatment directed to preserving mitochondrial function, anti-inflammation, wound healing and decreasing the signs of aging, as well as medicaments and their use are also provided.
Abstract: Drug formulations, methods and their use in treatment of diseases using formulations of pure di-acid salts of tetrandrine family members, especially d-tetrandrine di-hydrochloride, combined with a pharmaceutical diluent or carrier.
Abstract: Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.
Type:
Grant
Filed:
August 1, 2017
Date of Patent:
October 27, 2020
Assignee:
Augusta University Research Institute, Inc.
Abstract: Provided herein is an ophthalmic composition. In some embodiments, the ophthalmic composition includes a low concentration of an ophthalmic agent for treatment of an ophthalmic disorder or condition; and an ophthalmically acceptable carrier, wherein the ophthalmic agent is distributed with substantial uniformity throughout the ophthalmically acceptable carrier. Further disclosed herein include an ophthalmic composition including a low concentration of an ophthalmic agent and deuterated water. Also disclosed herein are methods of arresting or preventing myopia development by administering to an eye of an individual in need thereof an effective amount of an ophthalmic composition as described herein.
Type:
Grant
Filed:
June 22, 2020
Date of Patent:
October 27, 2020
Assignee:
SYDNEXIS, INC.
Inventors:
Gregory I. Ostrow, Kenneth J. Widder, David S. Baker, Harun Takruri
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating tuberculosis comprising compound (K279-1558) as an active ingredient. Compound (K279-1558) which is an active ingredient of the present invention has an effect of inhibiting the proliferation of M. tuberculosis by inducing apoptosis of macrophages infected with tuberculosis through the overexpression of p53. Therefore, the method of the present invention comprising said compound as an active ingredient could be usefully used for preventing or treating tuberculosis.
Type:
Grant
Filed:
April 23, 2019
Date of Patent:
October 20, 2020
Assignee:
THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY
Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.
Type:
Grant
Filed:
June 9, 2017
Date of Patent:
September 22, 2020
Assignee:
Oryzon Genomics, S.A.
Inventors:
Tamara Maes, Cristina Mascarò Crusat, David Rotllant Pozo